Identification of novel plasma proteomic biomarkers of Dupuytren disease
PLOS One · 18.03.2026 · 21 (3) · e0343733
DOI: 10.1371/journal.pone.0343733 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 18.03.2026. Verfasst von Blake Hummer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dupuytren Research Group, West Palm Beach, Florida, United States of America. Hauptthemen laut MEDLINE: Dupuytren Contracture, Biomarkers, Proteomics, Blood Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dupuytren Disease (DD) is a chronic progressive disease that can cause disabling hand deformities. The most common treatments have either high complication rates or high early recurrence rates. Dupuytren lacks a staging biomarker profile to inform the development of preventive therapeutics to improve long-term outcomes. This multi-omic study aimed to create a DD blood proteomic biomarker profile by comparing DD plasma with that of a healthy control group. We measured circulating collagen metabolism peptides and found normal Collagen I synthesis but impaired Collagen I degradation in DD. We measured 6995 serum protein aptamers and identified 68 proteins that showed statistically significant differences compared with the control group. We developed two Diagnostic Proteomic Risk Scores (DPRS) based on hypothesis-free and hypothesis-based analyses. In independent data, our hypothesis-free and hypothesis-based DPRS distinguished Dupuytren from control subjects with accuracies of 76.5% and 70.6%, respectively. Our hypothesis-based DPRS also distinguished DD subjects with different disease progression rates by age at their first corrective procedure (p = 0.0018). This pilot study is the first to provide evidence to suggest that Collagen I accumulation in DD results from impaired degradation rather than increased collagen synthesis. It also describes novel DPRS that have potential use as diagnostic and staging biomarker panels for Dupuytren disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dupuytren Research Group, West Palm Beach, Florida, United States of America.
- Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States of America.
- Department of Medicine, Tufts University, Boston, Massachusetts, United States of America.
- Department of Medicine, Computational Biomedicine Section, Chobanian and Avedisian School of Medicine, Boston University, Boston, Massachusetts, United States of America.
- Nordic Bioscience, Herlev, Denmark.
ORCID-Profile: Blake Hummer, Anastasia Leshchyk, Anastasia Gurinovich, Charles Eaton
Zitieren
APA
Hummer, B., Sebastiani, P., Leshchyk, A., Gurinovich, A., Bager, C., Karsdal, M., Nielsen, S., & Eaton, C. (2026). Identification of novel plasma proteomic biomarkers of Dupuytren disease. PLOS One, 21(3), e0343733. https://doi.org/10.1371/journal.pone.0343733
Vancouver
Hummer B, Sebastiani P, Leshchyk A, Gurinovich A, Bager C, Karsdal M, et al. Identification of novel plasma proteomic biomarkers of Dupuytren disease. PLOS One. 2026;21(3):e0343733. doi:10.1371/journal.pone.0343733
BibTeX
@article{Hummer2026,
author = {Hummer, Blake and Sebastiani, Paola and Leshchyk, Anastasia and Gurinovich, Anastasia and Bager, Cecilie and Karsdal, Morten and Nielsen, Signe and Eaton, Charles},
title = {Identification of novel plasma proteomic biomarkers of Dupuytren disease},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0343733},
doi = {10.1371/journal.pone.0343733}
}
EUVIMED